Paclitaxel-Coated Devices in Chronic Limb-Threatening Ischemia
According to a recent study, paclitaxel-coated devices do not reduce rates of major amputations in patients with chronic limb-threatening ischemia.
All-cause mortality and reduction in major amputations were similar between groups. The rate of target vessel reintervention was also similar in paclitaxel-coated and uncoated devices groups at 5 years.
Study Overview
This randomized controlled trial compared the rate of major ipsilateral amputation among patients with chronic limb-threatening ischemia who were treated with paclitaxel-coated versus uncoated devices.
Primary and Secondary Outcomes
The primary outcome of this study was ipsilateral major amputation (above the ankle), while the key secondary outcome was all-cause mortality.
Evidence Rating Level: 1 (Excellent)
Author's summary: Paclitaxel-coated devices do not reduce amputation rates.